RxDoctor Payments Data

Jason Knight, MD

Gynecologic Oncology · Kansas City, MONPI 1518115559

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 18.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $288 and has fallen 62.7% since, to $107 in 2025. That places this record below the midpoint for gynecologic oncology clinicians in MO, where the typical reported total is $1,520.

$1,024in general payments, 2019–2025

Across 13 payments — averaging $78.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tesaro, Inc.$189
  • Myriad Genetic Laboratories, Inc.$151
  • Biom'up France SAS$118
  • Intuitive Surgical$107
  • Dysis Medical, Inc.$102
  • GSK$100
  • plus $257 from 6 others

What the payments were for

  • Food & beverage$1,024100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,024 in reported general payments places this provider in the 40th percentile of 38 gynecologic oncology providers in Missouri.

See all gynecologic oncology providers in Missouri

Medicare billing

Part B allowed, 2024
$79,442
Medicare patients
115
Services billed
575

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Letrozole15$395
Dexamethasone11$174

Paid to pharmacies, not to this prescriber.

Other gynecologic oncology in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →